Pharmafile Logo

vaccine reimbursement

- PMLiVE

Grifols share results identifying early signs of Parkinson’s disease

Parkinson’s disease affects over six million people globally

- PMLiVE

Richmond Pharmacology appoints John Hotti as Chief Technology Officer

Hotti was previously Head of AI and CIO at Telrock Systems

- PMLiVE

Beyond the Linear Path: Leading with Your Full Self

Listen to the full episode here. In the latest episode of the Hear From Her podcast, Giulia Ghibellini (Teva Pharmaceuticals) and Professor Amanda Kirby (Do-IT Solutions) share how their experiences...

Medscape Education

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

- PMLiVE

Clasado appoints Sebastian Nummelin as new APAC Regional Director

Most recently Nummelin served as Director of APAC at TINE

Site Factor report illustrations

Why patient-centricity depends on site-centricity in clinical trials

Explore why patient-centricity in clinical trials relies on site-centricity, emphasising the need to design trials that empower site teams to better support patients.

Cuttsy + Cuttsy

- PMLiVE

Astellas’ application to EMA validated for treatment of muscle-invasive bladder cancer

Bladder cancer affects over 224,000 people annually in Europe, with over 30% of cases being muscle-invasive bladder cancer

- PMLiVE

CNX Therapeutics appoints David Flint as Chief Corporate Development Officer

Flint most recently held roles at UCB and Solvay

- PMLiVE

Potential US-Iran peace deal to redraw market winners and losers

With a 10-day ceasefire between Israel and Lebanon in effect, oil prices are retreating from recent highs

Before and after

From cloudy to clear: visualising complex data privacy information

Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.

Cuttsy + Cuttsy

- PMLiVE

Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan

The company has been given manufacturing and marketing authorisation for the therapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links